2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD20

CD20

CD20 is a 33-37 kDa non-glycosylated protein expressed specifically on the surface of normal and malignant B lymphocytes, and belongs to the MS4A (membrane-spanning 4-domain family A) protein family. CD20 is a general B-cell marker expressed by the majority of B cells starting from late pre-B lymphocytes (it is not expressed by pro-B lymphocytes), and its expression is lost in terminally differentiated plasmablasts and plasma cells. Early experiments suggested that it was important in the regulation of human B-cell activation, proliferation, and Ca2+ transport. However, CD20-deficient mice appeared normal. Hence, the exact biological function of CD20 and its physiological ligand remain to be fully defined.240 Regardless of the uncertainty in the biological role of this antigen, it is a good target for cancer immunotherapy.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991514
    MIL62
    		Inhibitor
    MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL).
    MIL62
  • HY-P992466
    SM09
    		Inhibitor
    SM09 is an anti-human CD20 antibody.
    SM09
  • HY-P99501
    Zuberitamab
    		Inhibitor 98.69%
    Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.
    Zuberitamab
  • HY-P991904
    TG20
    		Inhibitor
    TG20 is an anti-CD20 monoclonal antibody that binds to a specific discontinuous epitope on CD20 with a Kd of 10–20 nM. TG20 exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). TG20 also enhances complement-dependent cytotoxicity (CDC) activity. TG20 can be used in research on B-cell lymphomas .
    TG20
  • HY-P992445
    PRO131921
    		Inhibitor
    PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma.
    PRO131921
  • HY-P991903
    PSB102
    		Inhibitor
    PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20.
    PSB102
  • HY-P991545
    BVX20
    		Inhibitor
    BVX20 is a human monoclonal antibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL.
    BVX20
  • HY-P990138
    Anti-Monkey/Human CD20 Antibody (2H7)
    Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/human CD20. Anti-Monkey/Human CD20 Antibody (2H7) specifically depletes B cells. Anti-Monkey/Human CD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis.
    Anti-Monkey/Human CD20 Antibody (2H7)
Cat. No. Product Name / Synonyms Application Reactivity